The article details a marketing campaign by Generation Lab, a startup claiming to have developed a rejuvenation treatment called “1 Generation,” an injectable combination of two existing drugs. According to the company, the treatment “blocks the systemic spread of aging in the bloodstream, reawakens the body’s own repair mechanism and restores health and youth to multiple tissues.” The company offered exclusive access to a “private cohort” of trusted individuals under physician supervision, including celebrities, to receive the treatment. However, Generation Lab refused to disclose the identities of the two drugs, raising skepticism about the credibility of their claims.
The founder of Generation Lab, Irina Conboy, is a recognized researcher known for her work on parabiosis, a procedure that has shown to make old animals act younger by connecting their circulatory systems. Conboy asserts that the drug combination she has developed mimics the benefits of parabiosis without the need for blood exchange. Anecdotal evidence from Conboy, the company’s CEO, and a few other insiders suggests perceived improvements in energy, vision, physical performance, and other health metrics. However, the lack of transparency regarding the drug components and the plan to conduct a larger study with alternative medicine practitioners, some of whom have a history of promoting unproven treatments, further complicates the assessment of the treatment’s validity.